Mirae Asset Global Investments Co. Ltd. Has $1.03 Million Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Mirae Asset Global Investments Co. Ltd. lessened its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 13.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,141 shares of the biotechnology company’s stock after selling 1,075 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Ascendis Pharma A/S were worth $1,033,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of ASND. Signaturefd LLC grew its holdings in shares of Ascendis Pharma A/S by 13.2% during the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 80 shares in the last quarter. Bessemer Group Inc. boosted its stake in Ascendis Pharma A/S by 61.0% in the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 332 shares in the last quarter. Searle & CO. acquired a new stake in Ascendis Pharma A/S in the 2nd quarter valued at $205,000. Rhumbline Advisers boosted its stake in Ascendis Pharma A/S by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after buying an additional 143 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in Ascendis Pharma A/S in the 1st quarter valued at $288,000.

Ascendis Pharma A/S Trading Up 2.0 %

NASDAQ:ASND opened at $125.28 on Friday. Ascendis Pharma A/S has a 1 year low of $86.54 and a 1 year high of $161.00. The stock has a market cap of $7.60 billion, a price-to-earnings ratio of -13.46 and a beta of 0.64. The stock has a 50-day moving average price of $133.42 and a two-hundred day moving average price of $133.68.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The business had revenue of $38.75 million during the quarter, compared to analysts’ expectations of $94.74 million. Sell-side analysts forecast that Ascendis Pharma A/S will post -7.24 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $170.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, September 16th. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Thursday, September 5th. Jefferies Financial Group lifted their price objective on Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a research report on Tuesday, August 13th. Citigroup boosted their target price on Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. Finally, TD Cowen boosted their target price on Ascendis Pharma A/S from $157.00 to $160.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Ascendis Pharma A/S currently has a consensus rating of “Moderate Buy” and a consensus target price of $195.92.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.